SMART drug delivery systems: Double-targeted pH-responsive pharmaceutical nanocarriers

被引:416
作者
Sawant, R. M. [1 ]
Hurley, J. P. [1 ]
Salmaso, S. [1 ]
Kale, A. [1 ]
Tolcheva, E. [1 ]
Levchenko, T. S. [1 ]
Torchilin, V. P. [1 ]
机构
[1] Northeastern Univ, Dept Pharmaceut Sci, Boston, MA 02115 USA
关键词
D O I
10.1021/bc060080h
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
To develop targeted pharmaceutical carriers additionally capable of responding to certain local stimuli, such as decreased pH values in tumors or infarcts, targeted long-circulating PEGylated liposomes and PEG-phosphatidylethanolamine (PEG-PE)-based micelles have been prepared with several functions. First, they are capable of targeting a specific cell or organ by attaching the monoclonal antimyosin antibody 2G4 to their surface via pNP-PEG-PE moieties. Second, these liposomes and micelles were additionally modified with biotin or TAT peptide (TATp) moieties attached to the surface of the nanocarrier by using biotin-PE or TATp-PE or TATp-short PEG-PE derivatives. PEG-PE used for liposome surface modification or for micelle preparation was made degradable by inserting the pH-sensitive hydrazone bond between PEG and PE (PEG-Hz-PE). Under normal pH values, biotin and TATp functions on the surface of nanocarriers were "shielded" by long protecting PEG chains (pH-degradable PEG(2000)-PE or PEG(5000)-PE) or by even longer pNP-PEG-PE moieties used to attach antibodies to the nanocarrier (non-pH-degradable PEG(3400)-PE or PEG(5000)-PE). At pH 7.4-8.0, both liposomes and micelles demonstrated high specific binding with 2G4 antibody substrate, myosin, but very limited binding on an avidin column (biotin-containing nanocarriers) or internalization by NIH/3T3 or U-87 cells (TATp-containing nanocarriers). However, upon brief incubation (15-30 min) at lower pH values (pH 5.0-6.0), nanocarriers lost their protective PEG shell because of acidic hydrolysis of PEG-Hz-PE and acquired the ability to become strongly retained on an avidin column (biotin-containing nanocarriers) or effectively internalized by cells via TATp moieties (TATp-containing nanocarriers). We consider this result as the first step in the development of multifunctional stimuli-sensitive pharmaceutical nanocarriers.
引用
收藏
页码:943 / 949
页数:7
相关论文
共 33 条
[1]   Intracellular delivery of a Tat-eGFP fusion protein into muscle cells [J].
Caron, NJ ;
Torrente, Y ;
Camirand, G ;
Bujold, M ;
Chapdelaine, P ;
Leriche, K ;
Bresolin, N ;
Tremblay, JP .
MOLECULAR THERAPY, 2001, 3 (03) :310-318
[2]   TAT-MEDIATED DELIVERY OF HETEROLOGOUS PROTEINS INTO CELLS [J].
FAWELL, S ;
SEERY, J ;
DAIKH, Y ;
MOORE, C ;
CHEN, LL ;
PEPINSKY, B ;
BARSOUM, J .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1994, 91 (02) :664-668
[3]   Tumor cell targeting of liposome-entrapped drugs with phospholipid-anchored folic acid-PEG conjugates [J].
Gabizon, A ;
Shmeeda, H ;
Horowitz, AT ;
Zalipsky, S .
ADVANCED DRUG DELIVERY REVIEWS, 2004, 56 (08) :1177-1192
[4]   Intracellular delivery of large molecules and small particles by cell-penetrating proteins and peptides [J].
Gupta, B ;
Levchenko, TS ;
Torchilin, VP .
ADVANCED DRUG DELIVERY REVIEWS, 2005, 57 (04) :637-651
[5]   ATTACHMENT OF ANTIBODIES TO STERICALLY STABILIZED LIPOSOMES - EVALUATION, COMPARISON AND OPTIMIZATION OF COUPLING PROCEDURES [J].
HANSEN, CB ;
KAO, GY ;
MOASE, EH ;
ZALIPSKY, S ;
ALLEN, TM .
BIOCHIMICA ET BIOPHYSICA ACTA-BIOMEMBRANES, 1995, 1239 (02) :133-144
[6]   Recent advances in tumor-targeting anticancer drug conjugates [J].
Jaracz, S ;
Chen, J ;
Kuznetsova, LV ;
Ojima, L .
BIOORGANIC & MEDICINAL CHEMISTRY, 2005, 13 (17) :5043-5054
[7]   EVALUATION OF QUANTITATIVE PARAMETERS OF THE INTERACTION OF ANTIBODY-BEARING LIPOSOMES WITH TARGET ANTIGENS [J].
KLIBANOV, AL ;
MUZYKANTOV, VR ;
IVANOV, NN ;
TORCHILIN, VP .
ANALYTICAL BIOCHEMISTRY, 1985, 150 (02) :251-257
[8]  
Liang Wei, 2004, Current Drug Delivery, V1, P1, DOI 10.2174/1567201043480063
[9]   Drug delivery of oligonucleotides by peptides [J].
Lochmann, D ;
Jauk, E ;
Zimmer, A .
EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS, 2004, 58 (02) :237-251
[10]   Tumor-targeted liposomes: doxorubicin-loaded long-circulating liposomes modified with anti-cancer antibody [J].
Lukyanov, AN ;
Elbayoumi, TA ;
Chakilam, AR ;
Torchilin, VP .
JOURNAL OF CONTROLLED RELEASE, 2004, 100 (01) :135-144